Stability and survival analysis of elderly patients with osteolytic spinal bone metastases after palliative radiotherapy : Results from a large multicenter cohort.
Stabilitäts- und Überlebensanalyse geriatrischer Patienten mit osteolytischen spinalen Knochenmetastasen nach palliativer Radiotherapie : Ergebnisse einer großen multizentrischen Kohorte.
Aged
Fracture
Geriatrics
Neoplasm metastases
Spine
Journal
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
ISSN: 1439-099X
Titre abrégé: Strahlenther Onkol
Pays: Germany
ID NLM: 8603469
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
02
01
2019
accepted:
03
06
2019
pubmed:
27
6
2019
medline:
20
3
2020
entrez:
27
6
2019
Statut:
ppublish
Résumé
This retrospective study aimed to evaluate the stability and fracture rates of osteolytic spinal bone metastases (SBM) in elderly patients following palliative radiotherapy (RT) and to derive prognostic factors for stability and survival. A total of 322 patients aged at least 70 years received palliative RT at two major German academic medical centers or at the German Cancer Research Center. Stability assessment was based on the validated Taneichi score prior to RT and at 3 and 6 months after RT. The survival time following RT was assessed, and prognostic factors for stability and survival were analyzed. Prior to RT, 183 patients (57%) exhibited unstable SBM and 68 patients (21%) pathological fractures. At 3 and 6 months after RT, significant recalcification and stabilization were evident in 19% (23/118) and 40% (31/78) of surviving patients, respectively. Only 17 patients (5%) experienced new pathological fractures following RT. Tumor histology was found to significantly influence stabilization rates with only breast cancer patients exhibiting increased stabilization compared to patients with other histologies. The median survival time and 6‑month survival rates following RT were 5.4 months (95% confidence interval 4.4-7.2 months) and 48%, respectively. The patients' performance status was found to be the strongest predictor for survival after RT in this patient cohort; further factors demonstrating a significant association with survival were the application of systemic treatment, the number of SBM and the primary tumor histology. To analyze the influence of age on survival after RT, study patients were stratified into 3 age groups (i.e., 70-74 years, 75-79 years, and ≥80 years). The subgroup of patients aged at least 80 years showed a strong trend towards a worse survival time following RT compared to younger patients (i.e., 6‑month survival rate 39% vs. 51%; p = 0.06, log-rank test). Prognostic factors influencing overall survival such as performance status and histology should guide the choice for palliative RT for SBM. Strongly hypofractionated RT regimes may be advisable for most elderly patients considering the overall poor prognosis in order to reduce hospitalization times.
Identifiants
pubmed: 31240346
doi: 10.1007/s00066-019-01482-1
pii: 10.1007/s00066-019-01482-1
pmc: PMC6867989
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1074-1085Références
Am J Hosp Palliat Care. 2018 Apr;35(4):718-723
pubmed: 28950727
ESMO Open. 2016 Apr 12;1(3):e000020
pubmed: 27843603
Bone. 2015 Oct;79:176-82
pubmed: 26057367
Radiat Oncol. 2014 Sep 03;9:194
pubmed: 25182126
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Lancet Oncol. 2015 Apr;16(4):375-84
pubmed: 25795410
Neuro Oncol. 2014 Jul;16(7):991-8
pubmed: 24470544
Strahlenther Onkol. 1999 Oct;175(10):500-8
pubmed: 10554645
Strahlenther Onkol. 2014 Oct;190(10):919-24
pubmed: 24658606
Int J Radiat Oncol Biol Phys. 2011 Mar 15;79(4):965-76
pubmed: 21277118
BMC Cancer. 2014 Aug 14;14:589
pubmed: 25123656
Lancet. 2014 Feb 8;383(9916):549-57
pubmed: 24351322
J Clin Oncol. 2007 Apr 10;25(11):1423-36
pubmed: 17416863
Eur Spine J. 2018 Apr;27(4):799-805
pubmed: 29064040
Radiat Oncol. 2013 Aug 13;8(1):200
pubmed: 23937907
Anticancer Res. 2014 Nov;34(11):6641-5
pubmed: 25368269
Tumori. 2016 Mar-Apr;102(2):156-61
pubmed: 26166220
Radiol Oncol. 2017 Sep 14;52(2):189-194
pubmed: 30018523
BMC Musculoskelet Disord. 2018 Feb 5;19(1):38
pubmed: 29402261
Tumori. 2015 Nov-Dec;101(6):614-20
pubmed: 26108250
Radiat Oncol. 2018 Jul 24;13(1):134
pubmed: 30041672
Eur Spine J. 2003 Oct;12 Suppl 2:S202-13
pubmed: 14505120
Oncologist. 2006 Nov-Dec;11(10):1121-31
pubmed: 17110632
Strahlenther Onkol. 2014 Sep;190(9):792-7
pubmed: 24687563
Int J Radiat Oncol Biol Phys. 2014 Nov 15;90(4):739-47
pubmed: 25260489
Radiat Oncol. 2017 Jul 11;12(1):115
pubmed: 28697786
Eur J Cancer. 2017 Sep;82:155-166
pubmed: 28689093
Radiat Oncol. 2015 Aug 19;10:173
pubmed: 26282125
Spine (Phila Pa 1976). 1997 Feb 1;22(3):239-45
pubmed: 9051884
J Immunother Cancer. 2018 Apr 4;6(1):26
pubmed: 29618381
Cancer. 2005 Jan 15;103(2):320-8
pubmed: 15593360
Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):e117-20
pubmed: 22381902